- Home
- SENEB vs SYRE Comparison
SENEB vs SYRE Comparison
Compare SENEB & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- SYRE
- Stock Information
- Founded
- SENEB 1949
- SYRE 2013
- Country
- SENEB United States
- SYRE United States
- Employees
- SENEB N/A
- SYRE N/A
- Industry
- SENEB Packaged Foods
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- SYRE Health Care
- Exchange
- SENEB Nasdaq
- SYRE Nasdaq
- Market Cap
- SENEB 703.0M
- SYRE 841.4M
- IPO Year
- SENEB N/A
- SYRE 2016
- Fundamental
- Price
- SENEB $101.56
- SYRE $15.72
- Analyst Decision
- SENEB
- SYRE Buy
- Analyst Count
- SENEB 0
- SYRE 6
- Target Price
- SENEB N/A
- SYRE $55.00
- AVG Volume (30 Days)
- SENEB 568.0
- SYRE 697.4K
- Earning Date
- SENEB 08-07-2025
- SYRE 08-06-2025
- Dividend Yield
- SENEB N/A
- SYRE N/A
- EPS Growth
- SENEB N/A
- SYRE N/A
- EPS
- SENEB 5.90
- SYRE N/A
- Revenue
- SENEB $1,578,887,000.00
- SYRE N/A
- Revenue This Year
- SENEB N/A
- SYRE N/A
- Revenue Next Year
- SENEB N/A
- SYRE N/A
- P/E Ratio
- SENEB $16.89
- SYRE N/A
- Revenue Growth
- SENEB 8.25
- SYRE N/A
- 52 Week Low
- SENEB $57.51
- SYRE $10.91
- 52 Week High
- SENEB $107.99
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- SENEB 61.21
- SYRE 51.34
- Support Level
- SENEB $101.00
- SYRE $14.97
- Resistance Level
- SENEB $94.02
- SYRE $16.92
- Average True Range (ATR)
- SENEB 0.45
- SYRE 1.12
- MACD
- SENEB 0.22
- SYRE 0.02
- Stochastic Oscillator
- SENEB 58.86
- SYRE 58.05
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.